Molecular Testing Reimbursement

Molecular Testing Reimbursement

To reduce denials and protect molecular testing revenue it is imperative for laboratories to be aware of payer policy changes. As such some payers have established their own molecular policies while other payers follow the Palmetto LCD A58710 – this LCD is quite restrictive. Humana and UHC have been identified as following the Palmetto LCD. Due to the complexity in their requirements and the limited coverage, TELCOR recommends thoroughly reading the Palmetto article for information about billing and any additional information provided within the Group the CPT falls under. These sections often contain nuances that determine whether a claim is payable.

Overall, we believe laboratories that monitor payer policy adoption, understand LCD-specific nuances, and evaluate billing strategies proactively are best positioned to handle the challenges associated with molecular testing reimbursement.

- Kwami Edwards, Chief Operations Officer, RCM

 

PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released

PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released

Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.

Read More
TELCOR Promotions - November 2026

TELCOR Promotions - November 2026

Lincoln, NE – November 2026 TELCOR is proud to announce the promotion of Stephanie Gonnerman to Senior Analyst, Revenue Cycle Management (RCM).

Read More
Recently Released CLFS Data Reveal Large Differences in Test Volume by Laboratory Setting

Recently Released CLFS Data Reveal Large Differences in Test Volume by Laboratory Setting

The Centers for Medicare and Medicaid Services (CMS) released a report on Oct. 20 detailing significant differences in the share of reported test...

Read More